Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

Beer, 2011, The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study, BMC Neurol., 11, 144, 10.1186/1471-2377-11-144 Benson, 2014, Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years, Mult. Scler. Relat. Disord., 3, 186, 10.1016/j.msard.2013.06.004 Bermel, 2013, Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta, Ann. Neurol., 73, 95, 10.1002/ana.23758 Bloomgren, 2012, Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N. Engl. J. Med., 366, 1870, 10.1056/NEJMoa1107829 Bsteh, 2017, Discontinuation of disease-modifying therapies in multiple sclerosis – clinical outcome and prognostic factors, Mult. Scler., 23, 1241, 10.1177/1352458516675751 Calabresi, 2014, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol., 13, 545, 10.1016/S1474-4422(14)70049-3 Cohen, 2012, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, Lancet, 380, 1819, 10.1016/S0140-6736(12)61769-3 Coyle, 2013, Switching therapies in multiple sclerosis, CNS Drugs, 27, 239, 10.1007/s40263-013-0042-5 Devonshire, 2011, The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis, Eur. J. Neurol., 18, 69, 10.1111/j.1468-1331.2010.03110.x Gauthier, 2006, A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study, Autoimmun. Rev., 5, 532, 10.1016/j.autrev.2006.02.012 Gold, 2012, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N. Engl. J. Med., 367, 1098, 10.1056/NEJMoa1114287 Goodin, 2012, Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial, Neurology, 78, 1315, 10.1212/WNL.0b013e3182535cf6 1995, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group, Neurology, 45, 1277, 10.1212/WNL.45.7.1277 Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N. Engl. J. Med., 358, 676, 10.1056/NEJMoa0706383 Kappos, 2016, The 11-year long-term follow-up study from the randomized BENEFIT CIS trial, Neurology, 87, 978, 10.1212/WNL.0000000000003078 Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N. Engl. J. Med., 362, 387, 10.1056/NEJMoa0909494 Kister, 2016, Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study, J. Neurol. Neurosurg. Psychiatry, 87, 1133, 10.1136/jnnp-2016-313760 Kister, 2018, Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy, J. Neurol. Sci., 391, 72, 10.1016/j.jns.2018.06.001 La Mantia, 2014, Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis, Cochrane Database Syst. Rev., 10.1002/14651858.CD009333.pub2 Melesse, 2017, Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort, Patient Prefer. Adherence, 11, 1093, 10.2147/PPA.S138263 Mikol, 2008, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial, Lancet Neurol., 7, 903, 10.1016/S1474-4422(08)70200-X O'Rourke, 2005, Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns, Mult. Scler., 11, 46, 10.1191/1352458505ms1131oa Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med., 354, 899, 10.1056/NEJMoa044397 Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann. Neurol., 13, 227, 10.1002/ana.410130302 Reich, 2018, Multiple sclerosis, N. Engl. J. Med., 378, 169, 10.1056/NEJMra1401483 Rosenkranz, 2015, PML in a patient with lymphocytopenia treated with dimethyl fumarate, N. Engl. J. Med., 372, 1476, 10.1056/NEJMc1415408 Shirani, 2012, Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis, JAMA, 308, 247, 10.1001/jama.2012.7625 Tobin, 2015, Stopping immunomodulatory medications in MS: frequency, reasons and consequences, Mult. Scler. Relat. Disord., 4, 437, 10.1016/j.msard.2015.07.004 Tomassini, 2018, Predicting the profile of increasing disability in multiple sclerosis, Mult. Scler. Tortorella, 2005, Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis, J. Neurol. Sci., 239, 95, 10.1016/j.jns.2005.08.006 Tremlett, 2008, Relapses in multiple sclerosis are age- and time-dependent, J. Neurol. Neurosurg. Psychiatr., 79, 1368, 10.1136/jnnp.2008.145805 Wattjes, 2015, MRI in the diagnosis and monitoring of multiple sclerosis: an update, Clin. Neuroradiol., 25, 157, 10.1007/s00062-015-0430-y